The once-daily tablet combines 5 mg of saxagliptin with 10 mg of dapagliflozin. It received marketing authorisation from the European Commission on 19 July 2016 and is approved for use in adults with type 2 diabetes to improve glycaemic control when metformin and/or a sulfonylurea and one of the individual components of saxagliptin/dapagliflozin do not provide adequate control, or when in patients who are already being treated with the free combination of saxagliptin and dapagliflozin.
The UK list price for Qtern is £49.56 for 28 tablets. NICE will not appraise Qtern and hence decisions on its use in NHS England will be taken at a local level. The Scottish Medicines Consortium and the All Wales Medicines Strategy Group will appraise it in 2017.
The summary of product characteristics for Qtern can be accessed at http://www.medicines.org.uk/emc/medicine/32750.
